Israel

Omnix Medical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Omnix Medical Wins €10.8M in EIC Accelerator Funding

Lead Product(s): OMN6

Therapeutic Area: Infections and Infectious Diseases Product Name: OMN6

Highest Development Status: IND Enabling Product Type: Peptide

Partner/Sponsor/Collaborator: EIC Accelerator Programme

Deal Size: $13.0 million Upfront Cash: Undisclosed

Deal Type: Funding January 25, 2021

Details:

Funding secures the advancement of Omnix Medical’s lead compound OMN6 through Phase I and II clinical trials. OMN6 is a novel antimicrobial peptide for treating life-threatening infections caused by Gram-negative bacteria.

RedHill Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease

Lead Product(s): Upamostat

Therapeutic Area: Infections and Infectious Diseases Product Name: RHB-107

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 17, 2020

Details:

RHB-107 has demonstrated strong inhibition of SARS-CoV-2 viral replication in a human bronchial cell model and targets a host cell component involved in viral replication, minimizing potential for resistance due to viral mutations.